U
REGN icon

UBS’s Regeneron Pharmaceuticals REGN Stock Holding History

UBS’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$7.71M Buy
21,400
+6,200
+41% +$2.08M 0.01% 1663
2014
Q2 		$4.29M Buy
15,200
+9,400
+162% +$2.79M ﹤0.01% 2098
2014
Q1 		$1.74M Sell
5,800
-6,400
-52% -$1.97M ﹤0.01% 2914
2013
Q4 		$3.36M Buy
12,200
+3,000
+33% +$863K ﹤0.01% 2261
2013
Q3 		$2.88M Buy
9,200
+3,800
+70% +$1,000K ﹤0.01% 2220
2013
Q2 		$1.21M Buy
+5,400
New +$1.26M ﹤0.01% 3115

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS's REGN Position: Q3 2014 in Review

UBS increased its Regeneron Pharmaceuticals (REGN) stake by 18% in Q3 2014, buying an estimated $2.78M and bringing the position to 54,404 shares worth $19.6M. The position accounts for 0.01% of the portfolio, ranked #961.

UBS first reported a position in REGN in Q2 2013 and has held it in 6 quarters since. The position peaked at $25.8M in Q3 2013. 474 funds tracked by Wall St. Rank hold REGN as of Q3 2014.

  • UBS held 54,404 shares of Regeneron Pharmaceuticals worth $19.6M as of Q3 2014.
  • UBS bought 8,300 Regeneron Pharmaceuticals shares in Q3 2014, an estimated $2.78M.
  • Regeneron Pharmaceuticals made up 0.01% of UBS's portfolio in Q3 2014, its #961 holding.
  • UBS first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's Regeneron Pharmaceuticals position peaked at $25.8M in Q3 2013.
  • 474 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.